Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

被引：1
|
作者：
Goy, Andre
Williams, Michael E.
Besisik, Sevgi Kalayoglu
Drach, Johannes
Ramchandren, Radhakrishnan
Robertson, Michael J.
Avivi, Irit
Rowe, Jacob M.
Herbrecht, Raoul
Van Hoof, Achiel
Egyed, Miklos
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Heise, Carla
Witzig, Thomas E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3057.3057
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3057
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study
    Williams, Michael E.
    Goy, Andre
    Sinha, Rajni
    Besisik, Sevgi Kalayoglu
    Drach, Johannes W.
    Ramchandren, Rod
    Zhang, Lei
    Cicero, Sherri
    Fu, Tommy
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
    Goy, Andre
    Sinha, Rajni
    Williams, Michael E.
    Besisik, Sevgi Kalayoglu
    Drach, Johannes
    Ramchandren, Radhakrishnan
    Zhang, Lei
    Cicero, Sherri
    Fu, Tommy
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3688 - +
  • [3] Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study
    Goy, Andre
    Williams, Michael E.
    Besisik, Sevgi Kalayoglu
    Drach, Johannes
    Ramchandren, Radhakrishnan
    Zhang, Lei
    Cicero, Sherri
    Fu, Tommy
    Witzig, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S141 - S142
  • [4] Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study
    Goy, Andre
    Sinha, Rajni
    Williams, Michael E.
    Besisik, Sevgi Kalayoglu
    Drach, Johannes
    Ramchandren, Radhakrishnan
    Robertson, Michael J.
    Avivi, Irit
    Rowe, Jacob M.
    Herbrecht, Raoul
    Van Hoof, Achiel
    Egyed, Miklos
    Zhang, Lei
    Cicero, Sherri
    Fu, Tommy
    Witzig, Thomas E.
    BLOOD, 2012, 120 (21)
  • [5] SINGLE-AGENT LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA FOLLOWING BORTEZOMIB: EFFICACY, SAFETY AND PHARMACOKINETICS FROM THE MULTICENTER PHASE II MCL-001 "EMERGE" TRIAL
    Goy, A.
    Sinha, R.
    Vose, J.
    Adler, H.
    Bernstein, S.
    Robertson, M.
    Chen, N.
    Zhang, L.
    Cicero, S.
    Fu, T.
    Witzig, T.
    HAEMATOLOGICA, 2013, 98 : 478 - 478
  • [6] Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial
    Goy, Andre
    Kalayoglu Besisik, Sevgi
    Drach, Johannes
    Ramchandren, Radhakrishnan
    Robertson, Michael J.
    Avivi, Irit
    Rowe, Jacob M.
    Herbrecht, Raoul
    Van Hoof, Achiel
    Zhang, Lei
    Cicero, Sherri
    Fu, Tommy
    Witzig, Thomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (04) : 496 - 503
  • [7] MCL-002: UPDATED EFFICACY AND SAFETY RESULTS FOR LENALIDOMIDE VSINVESTIGATOR'S CHOICE MONOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Arcaini, L.
    Rule, S.
    Lamy, T.
    Walewski, J.
    Belada, D.
    Mayer, J.
    Radford, J.
    Jurczak, W.
    Morschhauser, F.
    Alexeeva, J.
    Biyukov, T.
    Patturajan, M.
    Bravo, M. L. Casadebaig
    Trneny, M.
    HAEMATOLOGICA, 2016, 101 : 476 - 476
  • [8] Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.
    Goy, A.
    Bernstein, S. H.
    Kahl, B. S.
    Djulbegovic, B.
    Robertson, M. J.
    Boral, A.
    Shi, H.
    Fisher, R. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 425S - 425S
  • [9] Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study.
    Goy, A
    Bernstein, S
    Kahl, B
    Epner, E
    Leonard, JP
    Stadtmauer, E
    Morgan, D
    Belt, R
    Baidas, S
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 575S - 575S
  • [10] Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
    Michael Wang
    Stephen J. Schuster
    Tycel Phillips
    Izidore S. Lossos
    Andre Goy
    Simon Rule
    Mehdi Hamadani
    Nilanjan Ghosh
    Craig B. Reeder
    Evelyn Barnett
    Marie-Laure Casadebaig Bravo
    Peter Martin
    Journal of Hematology & Oncology, 10
12345